Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lexaria Bioscience Corp. - Common Stock (NQ:LEXX)

1.040 +0.010 (+0.97%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lexaria Bioscience Corp. - Common Stock

< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
30 31 Next >
Why Is Lexaria Bioscience (LEXX) Stock Up Today?
Today, investors in Lexaria Bioscience and LEXX stock are seeing impressive gains as investors price a key catalyst into shares. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers 
Via Benzinga
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Positive Results from Pulmonary Hypertension Clinical Study
Via CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Positive Results from Pulmonary Hypertension Clinical Study
Via Investor Brand Network
Why Lexaria Shares Are Rising Today
 
Via Benzinga
Lexaria's Pulmonary Hypertension Clinical Study HYPER-H21-3 Delivers Positive Results
Data From This Human Study, Together With the Findings From Lexaria's Other Previously Announced Successful Studies, Intended To Support the Company's Plans To Seek Approvals by the U.S. Food and Drug... 
From Lexaria Bioscience Corp.
Via AccessWire
Lexaria Bioscience (NASDAQ: LEXX) Issues Update On Human Nicotine Study
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
Lexaria Bioscience (NASDAQ: LEXX) Issues Update on Human Nicotine Study
Via Investor Brand Network
Lexaria Bioscience (NASDAQ: LEXX) Begins Nicotine Formulation Creation, Evaluation Program
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Issues Update on Human Nicotine Study NIC-H22-1
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Issues Update on Human Nicotine Study NIC-H22-1
Via CannabisNewsWire
Lexaria Bioscience (NASDAQ: LEXX) Begins Nicotine Formulation Creation, Evaluation Program
Via Investor Brand Network
Lexaria Provides Update on Human Nicotine Study NIC-H22-1
- Lexaria's DehydraTECH-nicotine pouch performance will be compared to existing leading brands currently sold in the United States such as ON! and Zyn KELOWNA, BC / ACCESSWIRE / April 12, 2022 /... 
From Lexaria Bioscience Corp.
Via AccessWire
Lexaria Aims To Demonstrate DehydraTECH's Performance In Epilepsy Research
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Beginning of New Nicotine Formulation Creation, Evaluation Program
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Beginning of New Nicotine Formulation Creation, Evaluation Program
Via CannabisNewsWire
Lexaria (NASDAQ: LEXX) Aims to Demonstrate DehydraTECH’s Performance in Epilepsy Research
Via Investor Brand Network
Lexaria Begins New Nicotine Formulation Creation and Evaluation Program
KELOWNA, BC / ACCESSWIRE / April 11, 2022 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces it has entered... 
From Lexaria Bioscience Corp.
Via AccessWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Hopes to Demonstrate DehydraTECH’s Superior Performance in Ongoing Epilepsy Research Program
Via CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Hopes to Demonstrate DehydraTECH’s Superior Performance in Ongoing Epilepsy Research Program
Via Investor Brand Network
Lexaria Bioscience's 24th Patent Sets Stage For Market Opportunities In Australia
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.   
Via Benzinga
Lexaria Bioscience’s (NASDAQ: LEXX) 24th Patent Sets Stage for Market Opportunities in Australia
Via Investor Brand Network
Topics Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) 24th Patent Sets the Stage for New Market Opportunities in Australia
Via Investor Brand Network
Topics Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) 24th Patent Sets the Stage for New Market Opportunities in Australia
Via CannabisNewsWire
Topics Intellectual Property
Lexaria Bioscience Optimistic About Upcoming Hypertension Study
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.   
Via Benzinga
Lexaria Bioscience (NASDAQ: LEXX) Optimistic About Upcoming Hypertension Study
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Optimistic About Its Upcoming, Largest-Ever Hypertension Study
Via CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Optimistic About Its Upcoming, Largest-Ever Hypertension Study
Via Investor Brand Network
Lexaria's IP Portfolio Grows Following Receipt Of 24th Granted Patent
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria has received a new patent entitled “Compositions... 
Via Benzinga
Lexaria’s (NASDAQ: LEXX) IP Portfolio Grows Following Receipt of 24th Granted Patent
Via Investor Brand Network
Topics Intellectual Property
< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
30 31 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.